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Abstract  23 
Mutational signatures provide a powerful alternative for understanding the pathophysiology of cancer. 24 
Currently, experimental efforts aimed at validating and understanding aetiologies of cancer-derived 25 
mutational signatures are underway. In this review, we highlight key aspects of mutational signature 26 
experimental design and describe the analytical framework. We suggest guidelines and quality control 27 
measures for handling whole-genome sequencing data for mutational signature analyses and discuss 28 
pitfalls in interpretation. We envision that improved next-generation sequencing (NGS) technologies 29 
and molecular cell biology approaches will usher in the next generation of studies into aetiologies and 30 
mechanisms of mutational patterns uncovered in cancers. 31 
  32 
Article sections (Main text: 5,000 words) 33 
      34 
Introduction 35 
 36 
Somatic mutations arising through cell-intrinsic and exogenous processes mark the genome with 37 
distinctive patterns termed mutational signatures. The field began in 2012 with the demonstration of at 38 
least five such mutation patterns in breast cancers [1]. Subsequently, twenty-one substitution signatures 39 
were identifiable across thirty cancer types [2]. While there have been revisions of analytical 40 
components of this field, there is a parallel trajectory evolving, focused on experimental validation, 41 
delineating aetiologies and mechanisms of mutagenesis. This is important, as the field is quickly gaining 42 
traction in the clinical arena. To provide the required confidence that mutational signatures can be 43 
utilised clinically, it is necessary to cultivate supporting experimental evidence for mutational 44 
signatures to serve as potential biomarkers. 45 
      46 
Several experimental studies to validate mutational signatures have been conducted, employing various 47 
model systems including C. elegans, yeast, human cancer cell lines, organoids and induced pluripotent 48 
stem cells among others [3-14]. There are differences in how these studies were performed, how data 49 
were processed, analysed and interpreted with different algorithms.  50 
 51 
In this review, we present guidelines that we hope will facilitate future experiments and analyses. We 52 
focus on considerations in experimental design and on the computational framework for data analysis 53 
in mutational signature studies, particularly in human cellular model systems. We further discuss issues 54 
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that need to be contemplated when linking an environmental mutagen or a DNA repair process to a 55 
mutational signature, which is not as straightforward as may superficially seem. 56 
 57 
Experimental considerations 58 
 59 
Choice of cellular model system 60 
 61 
Three critical points require consideration when choosing a human cellular system for investigating 62 
mutagenesis: the average ploidy, its background (cancer versus non-cancerous), and the likelihood of 63 
on-going mutagenesis. 64 
 65 
Ideally, a cellular model with a diploid (or haploid) genome should be sought. Gene-editing a haploid 66 
or diploid model is more efficient than editing a polyploid model. Having a lower ploidy also results in 67 
greater proportional representation of mutations that arise in next-generation sequencing reads, 68 
increasing the sensitivity of mutation-detection. In a hyper-triploid (3n+) cell line like HeLa, newly 69 
acquired somatic mutations may be present in one allele out of three, reported in ~33% of reads (Figure 70 
1a). By contrast, a diploid line would report mutations with greater certainty, in ~50% of reads. There 71 
is also the consideration of sequencing cost: To achieve comparable sensitivity of mutation detection, 72 
sequencing a haploid line or experimental model with a smaller genome (e.g. yeast) would be more 73 
affordable than sequencing a diploid or polyploid human model system.  74 
 75 
Non-cancerous lines may be preferable because they are less physiologically abnormal. They may have 76 
“stemness” properties such as in induced pluripotent stem cells (iPSC), and embryonic stem cells (ESC), 77 
or they may have tissue-specific properties such as tissue-derived organoids and retinal pigment 78 
epithelial (RPE1) cells. Non-cancerous lines are, however, more challenging to grow in culture and less 79 
tolerant of manipulation. They may be less likely to manifest mutational signatures because DNA repair 80 
and checkpoint pathways are functioning appropriately (or more so) and are thus less permissive for 81 
revealing mutagenesis. For example, TP53-intact iPSCs do not tolerate double-strand breaks (DSBs), 82 
tend to undergo apoptosis quickly and do not generate rearrangements patterns. Stem cells may also 83 
have other physiological properties that effectively protect them in their “stemness” state and this could 84 
have consequences on the likely manifestation of DNA damage, for example, biochemical inactivation 85 
of certain drugs because of higher expression of metabolic enzymes or enhanced drug efflux because 86 
of higher expression of multifunctional efflux transporters [15, 16].  87 
 88 
By contrast, cancer cell lines thrive in culture and will more likely yield patterns of genomic instability. 89 
Nonetheless, they often have severely abnormal physiological backgrounds, a multitude of pathway 90 
abnormalities acquired in vivo and ex vivo and carry highly disarrayed genomes (Figure 1b). Cancer 91 
cell lines derived from patients with relapsed disease are likely to be even more pathophysiologically 92 
awry, with effects on mutational outcome [17]. Such lines will have been exposed to a multitude of 93 
natural and iatrogenic insults, may have highly disordered genomes and been subjected to extensive 94 
rounds of selection pressure promoting evolvability within the cell population. This could culminate in 95 
increased mutagenesis. Counter-intuitively, it could also result in reduced mutagenesis if the 96 
physiological compensation to overcome selective pressure leads to physiological shifts that tend to 97 
suppress DNA damage [17]. The chosen biological model must also be amenable to clonal expansion 98 
following single-cell bottlenecking, and here, cancer cell lines tend to fare better than immortalised 99 
normal cells.  100 
 101 
Additionally, it is crucial to know whether a cell line model already carries intrinsic, on-going 102 
mutagenesis because profound intrinsic mutational patterns could drown out the signals being sought. 103 
For instance, the colorectal cancer cell line DLD-1 BRCA2KO – albeit a bona fide mismatch repair-104 
deficient cell line – is often used as an HR-deficient model due to its BRCA2 knock-out (KO) status. 105 
WGS of DLD-1 BRCA2KO cells, however, shows marked mutational signatures associated with MMR 106 
deficiency (Figure 1b), likely to obscure subtler signals from BRCA2 deficiency or anything else that 107 
would be engineered into this model system.  108 
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 109 
Some mutagenesis experiments may require an on-going mutational signature in order to dissect 110 
mechanisms of mutation formation. In that instance, it would be valuable to identify cell lines with an 111 
on-going signature of interest, and engineer perturbations to see how the signature deviates from its 112 
intrinsic state.  113 
 114 
In a proof-of-principle study, we demonstrated the feasibility of recreating cancer mutational signatures 115 
in vitro using CRISPR-Cas9 gene editing in a near-haploid cell model system, HAP-1 [7]. This cell line 116 
does not have intrinsic mutagenesis. It does, however, demonstrate the usual background mutagenesis 117 
associated with cell culture that results in C>A mutations (Figure 1b), thought to be caused by oxidative 118 
stress [18, 19]. In contrast to cancer cell lines such as H1299, MDA-MB-231, HeLa which have higher 119 
average ploidy, HAP-1 is also haploid – thus, sequencing was more affordable (only sequenced to 15x). 120 
That it has a propensity to revert to a diploid state is however recognised, and regular inspection must 121 
be implemented to detect such a situation for long-term maintenance in culture [20, 21].  122 
 123 
To investigate mutagenesis in cellular models, an isogenic “grandparental” sample of the cellular model 124 
system of choice should be used as the genetic reference from which all parental clones are derived 125 
(Figure 2). Here, parental clones refer to a single-cell derived colony that has been through a particular 126 
experimental process, such as gene-editing of a particular locus and then selected for the desired feature 127 
(e.g. knockout of gene X) or exposure to a genotoxin with recovery post-exposure.  128 
 129 
Genetic manipulation to generate gene-edited parental clones 130 
 131 
Most mutational signatures extracted from cancers are either associated with exogenous mutagen 132 
exposures (e.g. Signature 7 with UV; Signature 22 with aristolochic acid) or dysregulation of key DNA 133 
repair/replication genes (e.g. Signature 3 with BRCA1/BRCA2 gene mutations; Signature 10 with POLE 134 
mutations). One of the most straightforward experimental strategies to explore mutational signatures is 135 
therefore to knock-out a gene of interest, knock-in an activating mutation or over-express a particular 136 
protein, to see if the genetic manipulation instigates mutagenesis.  137 
 138 
To generate knockouts, aliquots of cells are exposed to reagents designed to target genes of interest. 139 
Negative editing controls should be included in parallel experiments, in which cells receive no 140 
manipulations or non-targeting versions of gRNA. These controls are informative of background and/or 141 
intrinsic mutagenesis inherent to the cell line models. Following enrichment of edited cells by selection 142 
markers – most commonly in the form of a fluorescence reporter or an antibiotic resistance gene – 143 
multiple single-cell edited clones can be isolated and screened. Those carrying desired mutations in the 144 
given gene are designated parental clones (Figure 2a). In scenarios where an empty vector or a 145 
scrambled gRNA control is unavailable, a clone that has been through targeting for gene knockouts but 146 
has nevertheless survived without biallelic alteration in the given gene could be used as the "wildtype" 147 
control. 148 
 149 
In a knockout or knockdown experiment, loss or downregulation of the proposed target can be 150 
ascertained through the confirmation of protein loss via western blot or mass spectrometry [22]. 151 
Functional assays may be performed — for example, RAD51 formation assay for an HR gene knockout, 152 
although the directness of these relationships is often assumed.   153 
 154 
Once verified, parental clones are cultured for a designated period to allow mutation accumulation 155 
(Figure 2a). The time required for mutation accumulation may vary between targeted genes and would 156 
need to be determined empirically, striking a balance between time in culture and the cost of the 157 
experiment.  158 
 159 
Some gene KOs may not produce discernible mutational signatures owing to low rates of mutagenesis 160 
under standard cell culture conditions. Artificially inducing DNA damage such as with cisplatin could 161 
magnify mutagenesis beyond its intrinsic baseline mutation rate, increasing the likelihood of uncovering 162 
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a signature. It could, however, produce a non-physiological pattern because of the exogenous stressor 163 
and thus, interpretation of such patterns should be made with the experimental set-up in mind. Using 164 
alternative isogenic models that are more permissive for mutagenesis (e.g. mouse embryonic 165 
fibroblasts, chicken DT40 lymphoblast cell line or cancer cell lines) may increase mutation rates 166 
[23-28]. However, using different cell-based systems of different species or with different genetic 167 
backgrounds could result in diverse mutational signatures and must be taken into consideration when 168 
interpreting data. For example, cyclophosphamide and cisplatin signatures in DT40 are different to 169 
those observed in human cellular models [28].  170 
      171 
Genotoxin exposure 172 
 173 
To interrogate mutational signatures associated with exposures to environmental mutagen or 174 
genotoxins, aliquots of an isogenic cell line are treated with the chemical in question (Figure 2b). 175 
Appropriate solvent controls must be considered. For example, cisplatin stock should be constituted in 176 
0.9% NaCl instead of DMSO as the latter could cause ligand displacement and reduce cytotoxic effects 177 
of the compound. Furthermore, when treated with cisplatin, cells should be treated with 0.9% NaCl in 178 
a parallel control experiment to detect potential mutagenesis incurred by the solvent. In addition, many 179 
compounds are pro-mutagens and require cytochrome P450-mediated metabolic activation into DNA-180 
reactive intermediates to exert DNA damaging effects. Accordingly, when using these mutagens, the 181 
experiments could be performed in the absence and presence of an exogenous metabolising system such 182 
as the S9 rodent liver-derived metabolic enzyme mixture with the mutagen of interest. 183 
 184 
Treating cells with either a chronic, low-dose or punctuated, high-dose exposure becomes another point 185 
to consider. Typically, half-maximal inhibitory concentration (i.e. IC50 dose) of a compound is used as 186 
a starting point. In a previous study, we treated human iPSCs with 79 environmental mutagens using 187 
doses corresponding to either the IC50s or IC80s of the compounds for 2 to 24 hours, followed by 188 
single-cell bottleneck subcloning upon treatment recovery [8]. Notably, these cells were treated only 189 
once. Repeated cycles of treatment following recovery could conceivably increase mutation burden. 190 
Selection of resistant clones might, however, develop during a chronic experimental process and needs 191 
to be considered particularly if no signatures are seen when they were expected. 192 
Following treatment, successful DNA damage induction is most commonly confirmed via 193 
immunofluorescence staining or Western blotting of DNA damage response proteins. Routinely, 194 
gH2Ax, phospho-p53, phospho-p21, pRPA, pATM, pATR are used as markers for confirming DNA 195 
damage and DNA damage response (DDR) signalling. Nevertheless, successful DNA damage induction 196 
does not always correlate with mutagenic outcome; the reverse is also true [8]. For instance, 197 
formaldehyde treatment does not induce detectable DDR signalling in human iPSC cells but is 198 
associated with a mutation pattern; whereas acetaldehyde and acrylamide are able to elicit DDR, but do 199 
not produce detectable mutation patterns [8]. Thus, DDR induction does not necessarily predict 200 
mutagenesis.  201 
Mutation accumulation phase 202 
 203 
To detect mutation patterns in experiments involving gene-editing, the parental clone is grown under 204 
standard culture conditions, for an empirically-determined number of cell doublings to allow for 205 
mutations to accrue at a steady state (Figure 2a). For accurate estimation of mutation rate per cellular 206 
division, proliferation assays could be considered to determine the doubling time of the parental clones. 207 
For experiments involving exposure to environmental mutagens or protein overexpression, mutations 208 
accumulate as a consequence of the exposure. Cells are usually given time to recover post-exposure. 209 
 210 
At the end of the mutation accumulation phase, the parental cell population will have increased in size 211 
and be polyclonal, meaning that each cell will carry its own set of mutations, although some very early, 212 
shared mutations may be present. Thus, it is necessary to perform a single-cell subcloning step at the 213 
end of mutation accumulation in the parental clone (Figure 2). 214 
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 215 
Single-cell bottleneck 216 
 217 
Following expansion of parental clones, multiple single-cell subclones can be derived through limiting 218 
dilution or fluorescence-activated cell sorting with a flow cytometer (FACS). This single-cell bottleneck 219 
is necessary to permit seeing mutagenesis that has arisen in individual cells in the parental population 220 
using current sequencing technologies. Multiple subclones are required for each gene-edit or treatment 221 
condition, and serve as technical replicates, permitting assessment of consistency of mutational 222 
signatures between different subclones. Generally, we find that sequencing more replicate subclones 223 
(>=3) provides greater discriminatory power to discern mutational signatures than increasing mutation 224 
accumulation time in culture. 225 
 226 
To ensure subclones are derived from a single cell, cellular isolation can be monitored real-time using 227 
live-cell analysis systems such as an IncuCyte. If a live-cell stain (e.g. Calcein) is used, single-cell 228 
sorted culture plates can be imaged with fluorescence microscopy to confirm that each well only 229 
contains a single cell. 230 
 231 
Subclones are expanded in culture until sufficient cell numbers are reached for WGS without PCR 232 
amplification. For customary 30-fold WGS, approximately 250-500 ng of genomic DNA is required. A 233 
diploid human cell contains roughly six pg of genomic DNA. Thus, approximately 100,000 cells are 234 
needed for whole-genome sequencing a sample. 235 
 236 
Computational analysis 237 
 238 
WGS is performed on single-cell derived subclones following mutation accumulation. The 239 
grandparental sample is used as the genetic reference to subtract variants that have arisen prior to the 240 
grandparental sample and to subtract all shared variants in the parental samples. This allows detection 241 
of new (de novo) mutations that arise as a consequence of experimental manipulation. Alternatively, 242 
parental clones can also be used as a reference, although this would incur extra sequencing costs as 243 
many additional parental clones would need to be sequenced.   244 
 245 
After obtaining WGS, short-read sequences of all samples are independently aligned to the reference 246 
genome. All classes of somatic mutations are called in subclones against the parental/grandparental 247 
clone. In the following section, we demonstrate the use of WGS data for assessing the quality of and 248 
relationships between experimental samples and for determining experimentally-derived mutational 249 
signatures.  250 
 251 
      252 
Quality control 253 
      254 
To ensure the observed mutational signatures are correctly associated with the proposed experimental 255 
conditions, several essential quality control steps may be implemented (Figure 3a). 256 
      257 
First, WGS offers a rapid, direct way of checking the genotype of an edited cell line. Successful 258 
CRISPR-Cas9 editing of a gene should result in a frameshift indel near the gRNA targeted sequence.  259 
 260 
Similarly, off-target effects can be detected by explicitly seeking frameshift indels and large structural 261 
variants in the rest of the genome. Potential off-target sites for a given gRNA sequence can be queried 262 
by using relevant bioinformatic tools, e.g. COSMID (http://crispr.bme.gatech.edu) [29] and WGE 263 
(https://www.sanger.ac.uk/htgt/wge/) [30]. Unintended edits might affect a critical gene and result in 264 
unexpected mutator phenotypes.  265 
 266 
Moreover, it is important to ensure that the model system remains stable and does not develop overt 267 
malignant potential through the experimental process. As a rule of thumb, chromosome copy number 268 
  6 
in all subclones should remain relatively unchanged from their parent unless the treatment or edits are 269 
expected to generate copy number variation. Evidence of selection, including clonal and subclonal 270 
mutations in all DNA repair genes and TP53, and driver amplifications should remain absent from all 271 
samples. To ensure that experimentally-generated signatures are not a consequence of another genetic 272 
defect acquired during culture or treatment, mutations in coding sequences that could influence 273 
mutational outcomes should be sought. 274 
 275 
Second, variant allele fractions (VAF) can be used to ascertain whether subclones were derived from 276 
single cells. For a single-cell derived sample, all acquired mutations should have VAFs of ~ 0.5 in a 277 
diploid model because they are present on one of two possible alleles in a heterozygous state (Figure 278 
1a). Likewise, for haploid and triploid cells, the VAFs are expected to be normally distributed around 279 
1 and 0.33, respectively. Deviation of VAF distribution from the expected may indicate impurity of 280 
single-cell isolation (Figure 3a). Critically, polyclonal or mosaic subclones often show lower average 281 
VAFs and falsely elevated mutation burdens, resulting in an overestimation of mutation numbers. 282 
Including these samples in the quantitative analysis will likely confound the estimation of mutation rate 283 
and burden associated with a particular experimental condition. Nevertheless, polyclonality most often 284 
does not alter the mutational profile of subclones, as the patterns may be qualitatively identical even if 285 
the quantitative burden of mutations is inaccurate.  286 
      287 
Lastly, the likelihood of laboratory errors increases when multiple experimental conditions are 288 
investigated simultaneously. To uncover laboratory mix-ups, relationships between parental clones and 289 
their respective subclones can be inspected to detect potential mislabelling of subclones. As all 290 
subclones are originally derived from their parental clones, all mutations detected in parental clones 291 
should be present in their respective subclones, but not in subclones derived from other parents. Based 292 
on this genetic concept of relatedness, surveying shared mutations among all samples would enable the 293 
identification of mislabelled samples (Figure 3b). 294 
 295 
Signature channels 296 
 297 
Each mutation type (substitution, double sub, indel, rearrangement) has its distinct set of channels that 298 
are used to define signatures. While it would be ideal to have identical channels for experimental data 299 
and cancer-derived data, this is not always possible because the burden of mutagenesis can vary greatly 300 
between experimental model systems. The ratio of mutations to signature channels is important to 301 
consider: too many channels for low yield of mutations will dilute any signal; likewise, too few channels 302 
may not offer the resolution required for deriving biological insights. Substitution channels of 303 
experimental models tend to be identical to the ones used for cancers.  Indel and rearrangement channels 304 
tend to be collapsed into fewer channels. To make a comparison with cancer-derived signatures, it is 305 
more effective to collapse cancer-derived signatures into the same channels as the experiments rather 306 
than stretching the experimental channels to suit the cancer-channels. 307 
 308 
Substitutions channels mirror that which is customarily used in literature. Sequence context 309 
immediately 5’ and 3’ to each mutated base is taken into consideration. Since there are six classes of 310 
base substitution (C>A, C>G, C>T, T>A, T>C, T>G) and 16 possible sequence contexts for each 311 
mutated base (5’ A, C, G or T and 3’ A, C, G or T), there are 96 possible trinucleotides for each 312 
signature. Double substitutions are two adjacent bases that are mutated, indicating the existence of 313 
commonly occurring mutagenic events that cause substitution mutation at neighbouring bases. Double 314 
substitution signatures can be defined by 78 strand-agnostic combinations [8, 31]. Here, the 5' and 3' 315 
sequence contexts are not commonly considered because it creates (4 x 78 x 4 = 1248) too many 316 
channels for the yield of double substitutions typically seen in a sample (often < 5 in untreated samples).  317 
Channels for small indels (< 100 bp) generally incorporate the class (deletion versus insertion), motif 318 
CG/TA content and size (1 bp or larger), as well as the nature of flanking sequence at the indel junction: 319 
repeat-mediated indels resulting from replication strand slippage or microhomology-mediated indels 320 
formed during the repair of DNA double-strand breaks, or none. If the motif is flanked by 321 
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polynucleotide repeats, the length of the repetitive sequence is also often considered. In some instances, 322 
the variation of indel classifications might be insightful in revealing the underlying mutagenesis 323 
patterns. For example, for mutagens that are known to preferentially affect particular nucleotide, it 324 
might be valuable to extend the indel classification to consider nucleotide types [8].  325 
Rearrangement signatures are broadly categorised based on four types of rearrangements, namely 326 
tandem duplications, deletions, inversions, and translocations, with further consideration of sizes of the 327 
rearranged fragments [7].  328 
Analytical framework to identify mutational signatures 329 
      330 
By comparing the mutational burdens and profiles of experimental subclones with controls, 331 
experimental conditions that effectively produce signatures can be identified. The determination of 332 
experimentally-generated mutational signatures may vary depending on experimental settings, but a 333 
general workflow encompasses: 1) identifying background/intrinsic signatures in the chosen cellular 334 
system; 2) detecting a quantitative difference in mutation counts between experimental subclones and 335 
controls; 3) detecting a qualitative difference in the mutational spectra between experimental subclones 336 
and controls; 4) subtracting background/intrinsic signatures to obtain experimentally-associated 337 
signatures; 5) evaluating the stability of extracted mutational signatures (Figure 4). 338 
  339 
Pervasive intrinsic signatures may be distinctive in different cell lines. Growing cells in culture also 340 
contributes substantial DNA damage that results in particular patterns (Figure 1b). These two potential 341 
sources of background mutagenesis are not negligible; thus, it is necessary to identify and subtract them 342 
to determine experimentally-generated mutational signatures. In practice, the averaged mutation burden 343 
and profile of control subclones can be used to represent the background or intrinsic mutagenesis of the 344 
chosen cellular system. 345 
  346 
The mutational profile of experimental cells is a linear combination of the mutational signature of 347 
background mutagenesis and the pertinent experimental manipulation. In principle, if a particular 348 
manipulation, whether mutagen treatment or gene-edit, generates mutational signatures, one would 349 
expect additional mutagenesis over and above background mutagenesis (Figure 4). To determine 350 
whether there is a significant quantitative increase of mutation numbers in experimental subclones 351 
compared to control, bootstrap resampling techniques can be used to construct an “expected” 352 
distribution of mutation burdens of control subclones. The likelihood (p-value) of observing a 353 
significantly different mutation burden for experimentally generated subclones can thus be calculated 354 
through a permutation test (Figure 5a).  355 
 356 
To ascertain whether there are qualitative differences in mutation profile between experimental 357 
subclones and controls, the distinction between mutation profiles can be measured by the “signal-to-358 
noise” ratio (SNR) (Figure 5b). The Euclidean distance between the mutational profiles of experimental 359 
versus control subclones defines the “signal”, while the variability of mutation profiles amongst 360 
subclones defines the “noise” parameter. A large SNR value indicates that the difference of mutational 361 
profiles between experimental subclones and controls is sufficiently distinguishable from their noises 362 
and, therefore, the experiment-associated signature may be separated from the background signature 363 
with relative ease. If there is inadequate number of controls for constructing a prior distribution, 364 
alternative methods including clustering approaches (e.g. tSNE or contrastive PCA) can be used to 365 
identify treated subclones that are distinct from controls. Notably, the number of subclones per 366 
experiment and the burden of mutation associated with each experiment are critical to the robustness of 367 
the results.  368 
 369 
The experiment-associated mutational signature can then be obtained by subtracting the background 370 
mutational signature from the mutational profile of treated subclones (Figure 4b).  To do so, each 371 
experimental subclone is bootstrapped to generate a distribution of mutation numbers for each signature 372 
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channel. Based on this distribution, the upper and lower boundaries (99% confidence interval, CI) of 373 
mutation numbers for each channel can be calculated. Likewise, a bootstrapped background signature 374 
profile can also be generated using the averaged mutation profile and mutation counts. This background 375 
can then be subtracted from the centroid of the bootstrapped experimental subclone profiles.  This may 376 
result in negative values for some channels. However, as long as the numbers fall within the 99% CI of 377 
the channels, negative values can be set to zero. Otherwise, the initial background mutation burden has 378 
to be reduced. 379 
Ideally, mutational signatures extracted from subclones of the same parental clone should be consistent 380 
(Figure 4b). However, variation may be observed among subclones, particularly when there is a low 381 
mutation burden associated with a particular experiment. The stability of a mutational signature can be 382 
reported by calculating the cosine similarity between signatures extracted from subclones. Higher 383 
cosine similarity (e.g. > 0.9) lends confidence to the accuracy of extracted mutational signatures. 384 
 385 
Discussion and perspective 386 
 387 
As an increasing number of mutational signatures in cancers are brought to light, studies offering 388 
experimental validation have also emerged.  389 
 390 
Association, not causation 391 
There remains a need for some caution in interpretation, even of experimental data. A particular 392 
perturbation such as treatment with a chemical, for example, 5-fluorouracil (5-FU) may produce a 393 
signature that we recognise [12]. In this case, Signature 17, characterised by T>G mutations, widely 394 
reported in cancers, of hitherto unknown aetiology. It would, however not necessarily follow that 5-FU 395 
directly causes Signature 17. Signature 17 is observed across a broad spectrum of primary tumours that 396 
have never been treated with 5-FU and arises spontaneously in untreated mouse embryonic fibroblasts 397 
[32-35]. It is far more likely that 5-FU is one of many compounds or physiological stressors of the cell, 398 
which in order to survive, requires a physiological adaptation that results in this hypermutator signature 399 
phenotype. In other words, the signature is a secondary, indirect effect of the treatment [36, 37]. These 400 
possibilities must be taken into consideration when interpreting signature data, regardless of whether 401 
experimental or cancer-derived. As an interesting example, the current COSMIC signature 11,  402 
characterized by C>T transitions was previously attributed to temozolomide because the signature was 403 
enriched in tumors of patients that had been treated with this alkylating agent [2]. However, systematic 404 
studies using the family of alkylating agents on human IPSCs suggest that the signature of 405 
temozolomide is defined by T>C mutations. Another alkylating compound, 1,2-DMH is instead similar 406 
to Signature 11 [8, 38].   407 
 408 
Fitting of a priori signatures 409 
Attributing aetiologies to mutational signatures is not as straightforward as may superficially seem. 410 
Supervised fitting of signatures could lead to falsely-suggested relationships. When we take a set of 411 
allegedly “known signatures” and ask the question which of those signatures are present in a new 412 
dataset, this process, called “fitting”, is purely mathematical. Presented with 20 potential signatures, the 413 
algorithm will do its best to fit all 20 signatures to the data, regardless of whether they are biologically 414 
present or not. Thus, presenting signatures that may not be present in a sample but asking the algorithm 415 
to fit it to the best of its ability, could result in reporting of biological processes that are not present in 416 
the sample.  417 
 418 
A particularly notorious example is the finding of the “smoking signature” or Signature 4 in a variety 419 
of different tumour types, even when it is unlikely that tobacco carcinogens could reach said tissue (e.g. 420 
prostate). That is because Signature 4 is dominated by C>A/G>T transversions and many other 421 
signatures also have similar C>A/G>T mutations. The fitting algorithm invokes Signature 4 in tissues 422 
that have C>A/G>T mutations because it is such a strong phenotype.  423 
 424 
Fitting other previously known signatures on experimental data would incur similar risks.  425 
 426 
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Using cosine similarity 427 
Mathematically, cosine similarity measures the similarity between two vectors, in this case, the 428 
resemblance between two multi-channel mutation profiles. However, it does not measure similarity 429 
equally across all signatures, working best for sparsely populated signatures that have prominent 430 
features (i.e. prominent peaks), and less effectively for flatter, nondescript profiles. Cosine similarity is 431 
also not a linear metric - a measure of 0.8, for example, does not imply a high level of correlation. While 432 
a measure of 0.99 by contrast, does imply a high level of correlation, it does not mean that they are the 433 
same or caused by the same mechanisms. Likewise, the same gene defect or exposure can cause slightly 434 
different mutational signatures in different tissues, cautioning against the blind reliance on this metric 435 
to assess similarity between signatures. 436 
 437 
Signatures and aetiologies do not necessarily have 1-to-1 mappings 438 
Some experiments can induce multiple signatures per treatment or knockout. If these signatures arise 439 
in different classes, they are immediately interpretable as distinct signatures of different classes. 440 
However, if a gene defect produces multiple mutational signatures of the same mutation class, it will 441 
not be possible to distinguish them from each other instantly. Additional genetic or physiological 442 
stressors may be required to separate two signatures of the same mutation class.  443 
 444 
Disparate mutational processes can also produce the same mutational signature outcome. For example, 445 
a classical T>A mutation signature that has been associated with aristolochic acid is nearly identical to 446 
the T>A signature induced by DiBenzo[a]pyrene Diol-epoxide (DBPDE), a polycyclic aromatic 447 
hydrocarbon that is present in tobacco smoke [8]. It is likely that these disparate compounds converge 448 
on the genome in the same way, producing an adduct on adenine that results in a similar outcome. This 449 
surprising, humbling result is one that underscores the reason why we cannot simply assume that we 450 
understand the full picture based on performing correlative genomic analyses alone. Fundamentally, a 451 
1-to-1 mapping of one gene to one signature or one mutagen to one signature is unlikely to be the norm.  452 
 453 
Signal sizes 454 
The mutation burden generated by different environmental mutagens and different gene knockouts is 455 
highly variable. In general, mutagenesis is more pronounced in experiments where external genotoxins 456 
are introduced. It is notable that many mutagens or gene knockouts do not produce a detectable increase 457 
in mutation burden in experimental systems; their signal sizes can be much lower than observed in 458 
human cancers. Several possible reasons might account for this. First, the cellular system of choice may 459 
have a genetic background that suppresses DNA damage. Second, excessive or lethal DNA damage 460 
might cause apoptosis in normal cells, e.g. TP53-intact iPSCs do not produce rearrangement signatures. 461 
Third, the culture time and proliferation rate of the cell might affect the rate of mutation accumulation 462 
and, therefore the signal size. Fourth, there is genetic redundancy of DNA repair in the cell. As a result, 463 
some DNA repair gene knockouts may not produce a direct mutational consequence. Fifth, some DNA 464 
repair pathways mainly target damage caused by external environmental mutagens, e.g. Xeroderma 465 
Pigmentosum (XP) genes of nucleotide excision repair are involved in repairing UV-induced 466 
cyclobutane pyrimidine dimers (CPDs). In normal cell culture condition (no UV radiation), XP gene 467 
knockouts indeed do not generate mutational signatures. 468 
 469 
Caution in using experimentally-generated signatures 470 
Environmental exposures that were the earliest to be associated with patterns in human cancers, well 471 
before the advent of whole-genome sequencing such as the signatures associated with tobacco, 472 
aristolochic acid and ultraviolet light, are precisely the experimental treatments with the largest signals. 473 
They are orders of magnitude higher in mutagenicity compared to many other mutagens, hence were 474 
readily detected in many different experimental models historically. We observed smaller signals from 475 
exposures that have weaker DNA damaging impact.  476 
 477 
In seeking new “environmental causes of cancer”, we must do so with some caution: Just because we 478 
now know the signatures associated with these other agents, does not mean that we can and should use 479 
all of these signatures in an a priori way to seek out new causes of cancer in all future cancer datasets. 480 
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Some thoughtful consideration is required. As mentioned previously, when using a set of a priori 481 
signatures, this purely mathematical step is designed to seek out all possible suggested signatures in the 482 
dataset, regardless of whether they are genuinely biologically there or not. Thus, we caution the (mis)use 483 
of experimentally-generated (or any) mutational signatures – poorly considered use of signatures during 484 
the fitting step could result in mistakenly interpreting the presence of an environmental mutagen when 485 
it is not in a new dataset. Indeed, mis-assigning the presence of an occupational mutagen, for example, 486 
could lead to legal claims that are inappropriate.  487 
 488 
Future directions in understanding mechanism 489 
Future studies to explore mutagenesis by inducing specific types of DNA damage in selective DNA 490 
repair defective genetic backgrounds represent an attractive avenue to fine-tune our understanding of 491 
and to gain further insights into the mechanisms of mutagenesis. To achieve that, direct, genome-wide 492 
unbiased and specific measurement of the DNA lesions and their repair is required. For example, by 493 
coupling Damage-seq with XR-seq for cisplatin damage [39-41] or DSBCapture seq [42] with whole-494 
genome sequencing for DSBs, one could map precisely where the damage occurs in the genome and 495 
chart how cells differentially repair or misrepair the induced damage in different parts of the genome. 496 
Dissecting these mechanisms will help us understand the regional heterogeneity in damage sensitivity 497 
and the accessibility and efficacy of DNA repair machinery. 498 
Decreased sequencing cost and technical advances in single-cell WGS, as well as long-read sequencing 499 
technologies (e.g. PacBio sequencing), will likely transform the field. Long-read sequencing could 500 
uncover more and resolve previously understudied large and complex structural variants [43]; single-501 
cell WGS would allow tens and hundreds of cells to be profiled in a single experiment, hence offering 502 
more statistical power while at the same time simplifying the experiments by circumnavigating the need 503 
for single-cell bottlenecking. Currently, single-cell WGS data still suffer from high levels of noise and 504 
artefact variants introduced during whole-genome amplification and cell lysis process [4]. When more 505 
single-cell WGS data become available, such artefactual signatures may be better defined and used for 506 
filtering out false-positive mutations. 507 
 508 
We hope the guidelines presented here could help streamline the design and analysis of future studies. 509 
 510 
Display items (5 items) 511 
Figure  512 
1. Choice of cellular model systems 513 
a) Effect of cellular ploidy on the proportion of NGS reads representing variant alleles and on 514 
variant allele fraction (VAF) distribution. Blue and yellow lines joined by a dotted line represent 515 
forward and reverse reads respectively (only parts of pair-end reads are shown). Horizontal red 516 
lines represent the position of a variant on the sequencing reads. NSCLC: non-small-cell lung 517 
carcinoma; CML: chronic myelogenous leukaemia; HPV: human papillomavirus; A1ATD: 518 
alpha-1-antitrypsin deficiency. b) Genome plots and 96-bar plots representing mutational 519 
profiles of different cell lines. Shown from the outermost rings (genome plots) moving inwards 520 
are (i) the karyotypic ideogram; (ii) base substitutions, plotted as rainfall plots 521 
(log10 (intermutation distance) on the radial axis; dot colour: blue, C>A; black, C>G; red, C>T; 522 
grey, T>A; green, T>C; pink, T>G); (iii) insertions shown as short green lines; (iv) deletions 523 
shown as short red lines; (v) major (green blocks, gain) and minor (red blocks, loss) copy 524 
number alleles; and (vi) rearrangements shown as central lines (green, tandem duplications; 525 
red, deletions). Mutation burdens are non-representative here as the different cell-lines have 526 
had different lengths of time in culture.  527 
 528 
Figure 529 
2. Experimental designs 530 
  11 
a) An example of a genetic manipulation experiment to link specific gene edit to mutational 531 
patterns. Note that upon parental clone derivation, mutations might accumulate over several 532 
cellular generations to reveal mutational patterns. The number of doublings (n) required for 533 
mutation accumulation is gene- and/or model system-specific. b) An example of a genotoxin 534 
treatment experiment to link specific genotoxin exposure to mutational patterns. Here, 535 
mutations accumulate as a result of treatment; treated cells (and controls) are effectively the 536 
parental clones. Repeated cycles of treatment following recovery may help amplify the signals 537 
by increasing the mutation burden. It is imperative to sequence grandparental clones as the 538 
‘normal’ genetic reference. The background mutagenesis can be determined through the control 539 
subclones. 540 
 541 
Figure 542 
3. Quality control (QC) of WGS data 543 
a) Using WGS data to perform QC on experimental samples. b) Using shared variants between 544 
parental and daughter subclones to identify relationships between samples. Three scenarios are 545 
presented. The upper panel shows two histograms per experiment, with the total number of 546 
mutations per sample (horizontal histogram) and shared mutations between samples (vertical 547 
histogram, in decreasing order). Subclones and parental subclones for each scenario are also noted. 548 
Subclones that share mutations are dotted black and connected with a line. Lower panel depicts 549 
hypothetical experiments. Shared mutations between daughter subclones and parental clones are 550 
indicated by red arrow. Scenario 1: all subclones are correctly derived from the same parental clone 551 
as they share mutations among themselves and with their designated parent, and also have unique 552 
mutations. Scenario 2: all subclones are derived from the same parental clone as they share high 553 
numbers of mutations among themselves but not with the sequenced parent. In this example, an 554 
incorrect parental clone (purple) has been sequenced. Scenario 3: Subclones are derived from a 555 
mixed parental population that did not arise from a single cell. Not all subclones shared a high 556 
number of mutations among themselves and with their sequenced parent. Subclone 1, 4 and 6 are 557 
likely from one lineage; subclone 2, 3 and 5 are from a different lineage. Note that clonal expansion 558 
for isolated daughter subclones is not depicted in the diagram for simplicity. 559 
 560 
Figure 561 
4. Principles of extracting mutational signatures from experimental samples 562 
a) Mutation burdens and profiles of human iPSCs treated with different environmental 563 
mutagens. Treatments that generate a mutational signature typically show increased mutation 564 
burdens and/or altered mutational profiles in the subclones compared to control (background). 565 
Note that effect sizes vary for different perturbations. b) Determining experimentally-generated 566 
mutational signatures. 567 
 568 
Figure 569 
5. Computational characterisation on experimentally-generated mutational signatures 570 
a) Determination of qualitative difference (i.e. mutation number increase) between 571 
experimentally-generated subclones and controls through a permutation test based on the 572 
distribution of baseline mutation burden in control subclones (orange). A p-value <= 0.01 573 
indicates significantly different mutation burden for experimentally-generated subclones (red). 574 
b) Schematic illustration of the distinction of mutational spectra between parental and daughter 575 
subclones using signal-to-noise ratio (SNR). The averaged Euclidean distance between the 576 
mutational profiles of experimentally-generated subclones and controls defines the “signal”, 577 
while the variability (consistency) of mutation profiles amongst subclones defines the “noise” 578 
parameter. Here, 𝝁𝑪𝒐𝒏𝒕𝒓𝒐𝒍	and 𝝁𝑬𝒙𝒑 denote the means of the mutational profiles of control 579 
subclones and experimental subclones, respectively; 𝝈𝑪𝒐𝒏𝒕𝒓𝒐𝒍	and 𝝈𝑬𝒙𝒑	denote the standard 580 
deviations of the mutation profiles of control and experimental subclones, respectively. In this 581 
example, subclones of experimental condition B can be more confidently separated from the 582 
control subclones. 583 
 584 
 585 
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